Van ECK Associates Corp Has $41.69 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Van ECK Associates Corp lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 58,533 shares of the biopharmaceutical company’s stock after purchasing an additional 397 shares during the quarter. Van ECK Associates Corp’s holdings in Regeneron Pharmaceuticals were worth $41,694,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $37,000. Truvestments Capital LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6 %

Shares of REGN stock opened at $674.27 on Friday. The stock’s 50 day simple moving average is $710.88 and its 200 day simple moving average is $901.80. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a market capitalization of $74.10 billion, a price-to-earnings ratio of 17.61, a PEG ratio of 2.38 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $11.86 EPS. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

Analysts Set New Price Targets

A number of brokerages have commented on REGN. Evercore ISI decreased their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.